Amgen is proud to be part of the American Heart Association Scientific Sessions 2022. While you are here, you can explore our latest scientific information and disease state education and learn about our long-term commitment to developing and delivering transformative medicines for patients with cardiovascular disease.
This video provides a brief explanation of the basic tenets of extrapolation as it pertains to biosimilars. (0:50)
This video provides a high-level overview of what a biological drug is and how it differs from a small molecule drug. (0:47)
This video provides a high-level overview of biosimilars. The main goal of biosimilars is to create a drug that is similar to a reference product. (0:42)
See how Otezla may work in psoriatic arthritis. The specific mechanism(s) by which apremilast exerts its therapeutic action is not well defined. (3:30)
Learn about the PALACE 4 clinical trial data in DMARD-naïve patients. (11:52)
Learn about the RELIEF clinical trial data. (11:14)
The information presented here is intended for healthcare professionals in the United States and has been reviewed in accordance with our US headquarter policies.
Are you a healthcare professional?
Learn about PROFICIO, Amgen’s program of clinical studies of evolocumab. Introducing VESALIUS-CV, a global initiative exploring the potential of evolocumab for the prevention of first CV events. This is an investigational study. Evolocumab is not indicated for this intended use.
Overview of the mechanism of LDL-C regulation and the role of PCSK9.
Speakers: Dominick J. Angiolillo, MD, PhD, FACC | Carl (Chip) Lavie, Jr, MD, FACC
Watch how LDL-C levels recommended by multiple cholesterol guidelines have decreased over time and understand current recommendations for very high-risk patients.
Learn how we can better manage cholesterol in high-risk patients and help reduce the risk of subsequent CV events.
Host: Pam R. Taub, MD, FACC, FASPC
Guest: Sripal Bangalore, MD, MHA
Learn about the MOA for EVENITY® (romosozumab-aqqg) in treatment of post-menopausal women who are at high risk of fracture.
Learn more about the Prolia® MOA for treatment of post-menopausal osteoporosis.
Watch Dr. Amar Majjhoo discuss the results of the SEAM-RA clinical trial on ENBREL as a monotherapy for maintaining remission in patients with RA. (29:06)
Watch Dr. Lawrence Leventhal discuss the results of the SEAM-PsA clinical trial on ENBREL as a monotherapy for treating patients with PsA. (19:36)
The Embark App provides patients with financial support information, medication reminders, injection site tracking & more—all in the palm of their hand. (4:05)
Watch a video about ENBREL Nurse Partners™ and how they can help your patient prepare for their first injection at home with supplemental support. (2:44)
Watch a video about ENBREL Support® services that provides helpful information for your patients on prescribed ENBREL therapy. (2:22)